Our cancer conference coverage focuses on scientific and clinical data presented at medical and scientific meetings run by societies and organizations such as AAI, AACR, ASCO, ASGCT, ASBMT, ASH, AUA, EACR, EAU, EBMT, ECCO, EHA, ESMO, SABCS & SITC.
Occasionally covered are themes such as innovation, nanotechnology, regenerative medicine, strategic issues in the biotechnology industry and promising scientific research in other therapeutic areas.
All the content is editorially independent, no post is sponsored and no paid advertising is accepted. Posts reflect the opinion of the author and not those of any employer or company.
Unsolicited guest posts are not accepted.
Some content (“Premium Content”) requires payment of a fee to access. All posts from 2010 and 2011 are free and open access.
Editor & Oncology Lead Writer
From September 2013, Sally Church, PhD has become the Editor of Biotech Strategy Blog and lead writer for oncology related content.
Sally is widely recognised as an oncology new products expert. She has appeared on CNBC and is frequently quoted by media outlets.
Back in 2011, Sally was named as one of the Top 50 women on Twitter, where as @MaverickNY she is a frequent commentator on oncology drug development. Sally uses the author name “MaverickNY” to identify her posts on this blog.
Since 2006, Sally has written over 1,000 posts on the widely acclaimed Pharma Strategy Blog which showcased her knowledge of cancer biology and new product development. As part of her “Making a Difference” series she regularly conducted interviews with oncology thought leaders. Sally now focuses her attention on writing for Biotech Strategy Blog.
With over 20 years experience in the pharmaceutical industry in the UK & United States, Sally has held executive positions in sales, marketing and new product development, and has received numerous business achievement awards.
At Novartis Oncology she co-led the initial US launches of Gleevec® in CML and GIST.
After 10 years as a successful consultant advising many of the world’s leading pharmaceutical and emerging biotech companies on strategic marketing and oncology new product development, Sally is now a full-time digital media entrepreneur through her company, Blue Ice Publishing LLC.
Sally’s qualifications includes a PhD from Kings College London, MBA from Rutgers, Master of Science in Human & Applied Physiology and undergraduate degree in Sports Science. She has also undertaken executive education in finance at Harvard Business School. A keen sportswoman, Sally has played at national and county level in cricket and hockey in the UK.
She devotes some of her spare time to charitable cancer causes and sits on the board of directors of a non-profit organization, GRACE (Global Resource for Advancing Cancer Education) which focuses primarily on lung cancer education.
At Health Journalism 2017 Sally spoke on Friday, April 21 2017 in a session moderated by Scott Hensley (NPR) on “How cancer patients are changing clinical trials.”